Symbols / MIST Stock $1.91 +0.79% Milestone Pharmaceuticals Inc.

Healthcare • Biotechnology • Canada • NMS
MIST (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO
Exch · Country NMS · Canada
Market Cap 227.91M
Enterprise Value -16.56M
Income -63.06M
Sales 1.55M
FCF (ttm) -28.90M
Book/sh 0.34
Cash/sh 6.46
Employees 38
Insider 10d
IPO May 09, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E -2.10
PEG
P/S 147.42
P/B 5.59
P/C
EV/EBITDA 0.27
EV/Sales -10.71
Quick Ratio 7.83
Current Ratio 8.01
Debt/Eq 139.76
LT Debt/Eq
EPS (ttm) -0.75
EPS next Y -0.91
EPS Growth
Revenue Growth
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-20
ROA -41.09%
ROE -229.65%
ROIC
Gross Margin 100.00%
Oper. Margin -11.16%
Profit Margin 0.00%
Shs Outstand 119.64M
Shs Float 14.07M
Insider Own 2.48%
Instit Own 26.80%
Short Float 8.78%
Short Ratio 3.29
Short Interest 10.33M
52W High 3.06
vs 52W High -37.75%
52W Low 1.00
vs 52W Low 90.50%
Beta 1.04
Impl. Vol. 2.72%
Rel Volume 0.10
Avg Volume 1.97M
Volume 192.05K
Target (mean) $6.50
Tgt Median $7.50
Tgt Low $2.00
Tgt High $8.00
# Analysts 6
Recom Strong_buy
Prev Close $1.89
Price $1.91
Change 0.79%
About

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.91
Low
$2.00
High
$8.00
Mean
$6.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-06 reit HC Wainwright & Co. Buy → Buy $8
2025-12-16 main Wells Fargo Overweight → Overweight $8
2025-12-15 up TD Cowen Hold → Buy $8
2025-12-15 main HC Wainwright & Co. Buy → Buy $8
2025-09-11 init Wells Fargo — → Overweight $4
2025-04-01 main HC Wainwright & Co. Buy → Buy $10
2025-03-28 reit HC Wainwright & Co. Buy → Buy $25
2025-03-17 reit HC Wainwright & Co. Buy → Buy $25
2025-02-28 reit HC Wainwright & Co. Buy → Buy $25
2025-01-27 reit HC Wainwright & Co. Buy → Buy $25
2024-10-14 reit HC Wainwright & Co. Buy → Buy $25
2024-08-22 reit HC Wainwright & Co. Buy → Buy $25
2024-08-22 init Rodman & Renshaw — → Buy $9
2024-07-01 reit HC Wainwright & Co. Buy → Buy $25
2024-05-30 reit HC Wainwright & Co. Buy → Buy $25
2024-05-16 reit HC Wainwright & Co. Buy → Buy $25
2024-03-22 reit HC Wainwright & Co. Buy → Buy $25
2024-03-05 main Piper Sandler Overweight → Overweight $5
2024-02-26 reit HC Wainwright & Co. Buy → Buy $25
2023-12-27 main TD Cowen Outperform → Outperform $9
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-16 OLIVETO JOSEPH GERARD Chief Executive Officer 36,500 $2.26 $82,490
2026-01-26 OLIVETO JOSEPH GERARD Chief Executive Officer 167,577 $1.93 $375,315
2026-01-26 OLIVETO JOSEPH GERARD Chief Executive Officer 66,600
2026-01-26 MULLER LORENZ ANDREW Officer 64,746 $1.93 $145,851
2026-01-26 MULLER LORENZ ANDREW Officer 20,100
2026-01-26 HASIJA AMIT Chief Financial Officer 70,252 $1.93 $158,209
2026-01-26 HASIJA AMIT Chief Financial Officer 20,100
2026-01-26 BHARUCHA DAVID Officer 70,252 $1.93 $158,209
2026-01-26 BHARUCHA DAVID Officer 20,100
2026-01-26 NELSON JEFFREY EDWARD Chief Operating Officer 70,252 $1.93 $158,209
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.55
0.00
-100.00%
1.00
-80.00%
5.00
Operating Revenue
1.55
0.00
-100.00%
1.00
-80.00%
5.00
Operating Expense
63.69
+51.27%
42.10
-32.20%
62.10
-3.94%
64.64
Research And Development
18.11
+26.13%
14.36
-53.76%
31.05
-22.04%
39.83
Selling General And Administration
45.58
+64.27%
27.75
-10.63%
31.05
+25.12%
24.81
Selling And Marketing Expense
28.30
+157.24%
11.00
-27.20%
15.11
+66.18%
9.10
General And Administrative Expense
17.27
+3.18%
16.74
+5.08%
15.93
+1.36%
15.72
Other Gand A
17.27
+3.18%
16.74
+5.08%
15.93
+1.36%
15.72
Total Expenses
63.69
+51.27%
42.10
-32.20%
62.10
-3.94%
64.64
Operating Income
-62.14
-47.59%
-42.10
+31.09%
-61.10
-2.44%
-59.64
Total Operating Income As Reported
-62.14
-47.59%
-42.10
+31.09%
-61.10
-2.44%
-59.64
EBITDA
-59.11
-56.23%
-37.83
+33.67%
-57.04
+2.16%
-58.30
Normalized EBITDA
-59.11
-56.23%
-37.83
+33.67%
-57.04
+2.16%
-58.30
Reconciled Depreciation
0.11
+8.57%
0.10
+14.13%
0.09
+3.37%
0.09
EBIT
-59.22
-56.10%
-37.94
+33.59%
-57.13
+2.15%
-58.39
Net Income
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Pretax Income
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Non Operating Interest Income Expense
-0.92
-257.46%
0.58
-58.74%
1.41
+12.68%
1.25
Interest Expense Non Operating
3.84
+7.18%
3.58
+40.21%
2.55
0.00
Net Interest Income
-0.92
-257.46%
0.58
-58.74%
1.41
+12.68%
1.25
Interest Expense
3.84
+7.18%
3.58
+40.21%
2.55
0.00
Interest Income Non Operating
2.92
-29.88%
4.16
+4.97%
3.97
+216.35%
1.25
Interest Income
2.92
-29.88%
4.16
+4.97%
3.97
+216.35%
1.25
Tax Provision
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Income From Continuing Operation Net Minority Interest
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Income From Continuing And Discontinued Operation
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Income Continuous Operations
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Normalized Income
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Net Income Common Stockholders
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Diluted EPS
-0.67
+51.80%
-1.39
-0.72%
-1.38
Basic EPS
-0.67
+51.80%
-1.39
-0.72%
-1.38
Basic Average Shares
62.21
+44.82%
42.96
+1.19%
42.45
Diluted Average Shares
62.21
+44.82%
42.96
+1.19%
42.45
Diluted NI Availto Com Stockholders
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Line Item Trend 2023-12-31
Total Assets
75.23
Current Assets
73.03
Cash Cash Equivalents And Short Term Investments
66.00
Cash And Cash Equivalents
13.76
Other Short Term Investments
52.24
Receivables
3.85
Other Receivables
2.42
Taxes Receivable
0.91
Accrued Interest Receivable
0.53
Inventory
Prepaid Assets
3.18
Total Non Current Assets
2.19
Net PPE
2.19
Gross PPE
2.38
Accumulated Depreciation
-0.19
Properties
0.00
Machinery Furniture Equipment
0.38
Other Properties
1.92
Leases
0.09
Total Liabilities Net Minority Interest
58.45
Current Liabilities
7.23
Payables And Accrued Expenses
5.97
Payables
3.98
Accounts Payable
3.98
Other Payable
Current Accrued Expenses
1.99
Pensionand Other Post Retirement Benefit Plans Current
0.71
Current Debt And Capital Lease Obligation
0.55
Current Capital Lease Obligation
0.55
Other Current Liabilities
Total Non Current Liabilities Net Minority Interest
51.23
Long Term Debt And Capital Lease Obligation
51.23
Long Term Debt
49.77
Long Term Capital Lease Obligation
1.46
Other Non Current Liabilities
Stockholders Equity
16.77
Common Stock Equity
16.77
Capital Stock
260.50
Common Stock
260.50
Share Issued
33.48
Ordinary Shares Number
33.48
Treasury Shares Number
0.00
Additional Paid In Capital
33.83
Retained Earnings
-326.03
Gains Losses Not Affecting Retained Earnings
Total Equity Gross Minority Interest
16.77
Total Capitalization
66.54
Working Capital
65.81
Invested Capital
66.54
Total Debt
51.77
Net Debt
36.01
Capital Lease Obligations
2.00
Net Tangible Assets
16.77
Tangible Book Value
16.77
Foreign Currency Translation Adjustments
Other Equity Interest
48.46
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-49.04
-70.00%
-28.85
+37.86%
-46.42
+11.52%
-52.47
Cash Flow From Continuing Operating Activities
-49.04
-70.00%
-28.85
+37.86%
-46.42
+11.52%
-52.47
Net Income From Continuing Operations
-63.06
-51.88%
-41.52
+30.44%
-59.69
-2.22%
-58.39
Depreciation Amortization Depletion
0.11
+8.57%
0.10
+14.13%
0.09
+3.37%
0.09
Depreciation
0.11
+8.57%
0.10
+14.13%
0.09
+3.37%
0.09
Depreciation And Amortization
0.11
+8.57%
0.10
+14.13%
0.09
+3.37%
0.09
Other Non Cash Items
3.84
+7.23%
3.58
+40.17%
2.55
Stock Based Compensation
7.46
+29.17%
5.78
-39.42%
9.53
+5.37%
9.05
Operating Gains Losses
0.01
0.14
Gain Loss On Sale Of PPE
0.00
-100.00%
0.01
0.00
-100.00%
0.14
Change In Working Capital
2.68
-26.59%
3.66
+194.13%
1.24
+138.11%
-3.26
Change In Receivables
-1.12
-176.51%
1.46
+155.34%
-2.64
-261.37%
-0.73
Change In Inventory
-0.65
0.00
Change In Prepaid Assets
0.03
-97.83%
1.34
-52.67%
2.83
+265.71%
-1.71
Change In Payables And Accrued Expense
4.43
+406.51%
0.88
-15.54%
1.04
+214.22%
-0.91
Change In Other Working Capital
-0.01
+29.41%
-0.02
-194.44%
0.02
-77.78%
0.08
Investing Cash Flow
11.25
+35.77%
8.28
+74.16%
4.76
+108.33%
-57.12
Cash Flow From Continuing Investing Activities
11.25
+35.77%
8.28
+74.16%
4.76
+108.33%
-57.12
Net PPE Purchase And Sale
-0.30
-815.15%
-0.03
+70.54%
-0.11
+58.82%
-0.27
Purchase Of PPE
-0.30
-815.15%
-0.03
+70.54%
-0.11
+58.82%
-0.27
Capital Expenditure
-0.30
-815.15%
-0.03
+70.54%
-0.11
+58.82%
-0.27
Net Investment Purchase And Sale
11.55
+38.86%
8.32
+70.83%
4.87
+108.56%
-56.85
Purchase Of Investment
-82.92
+26.98%
-113.55
+17.19%
-137.13
-59.73%
-85.85
Sale Of Investment
94.47
-22.49%
121.87
-14.18%
142.00
+389.66%
29.00
Financing Cash Flow
85.53
+166.28%
32.12
-32.79%
47.79
+1447.67%
3.09
Cash Flow From Continuing Financing Activities
85.53
+166.28%
32.12
-32.79%
47.79
+1447.67%
3.09
Net Issuance Payments Of Debt
0.00
-100.00%
50.00
0.00
Issuance Of Debt
0.00
-100.00%
50.00
0.00
Long Term Debt Issuance
0.00
-100.00%
50.00
0.00
Net Long Term Debt Issuance
0.00
-100.00%
50.00
0.00
Net Common Stock Issuance
51.01
+87.13%
27.26
0.00
-100.00%
2.63
Proceeds From Stock Option Exercised
34.52
+610.10%
4.86
+746.86%
0.57
+25.33%
0.46
Net Other Financing Charges
-2.78
Changes In Cash
47.73
+313.12%
11.55
+88.67%
6.12
+105.75%
-106.50
Beginning Cash Position
25.31
+83.97%
13.76
+80.20%
7.64
-93.31%
114.14
End Cash Position
73.05
+188.56%
25.31
+83.97%
13.76
+80.20%
7.64
Free Cash Flow
-49.34
-70.85%
-28.88
+37.94%
-46.54
+11.77%
-52.74
Amortization Of Securities
-0.08
+82.16%
-0.45
-180.25%
-0.16
-67.01%
-0.10
Common Stock Issuance
51.01
+87.13%
27.26
0.00
-100.00%
2.63
Issuance Of Capital Stock
51.01
+87.13%
27.26
0.00
-100.00%
2.63
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category